novo nordisk semaglutide shortage Ozempic's patent problem: how lost control of a blockbuster drug. 💉 Demand for GLP-1 weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite Wegovy Obesity Drug Shortage: Novo

If you experience a suspected side effect from any topical product, including cosmetic formulations, you can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk

Consolidated extraction and conversion of baicalin to baicalein from Oroxylum indicum using a novel NADES-UAE system and bioactivity evaluation in RAW 264.7 cells

States with no obesity GLP-1 coverage: Most remaining states including Texas, Florida, Ohio, New Jersey, and Georgia do not cover GLP-1s for obesity at all

Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR

In other patients with vitamin B12 deficiency, the duration of therapy and route of administration will depend upon the cause and whether or not it is reversible

established a correlation between citrinin content and antioxidant activity as measured by the -carotene bleaching assay (Garca-Nicols et al., 2023)